• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

2016 "The Year of the Lay-Offs"





Sales numbers suck? Says who? Dexilant is a blockbuster drug. Contrave is the leader in the obesity class, Brintellix has been the best PCP drug launch in the last 10 years and Amitiza is growing like crazy due to OIC indication. Haters going to hate, but things are looking damn good at Takeda!

Funniest thing ive heard in a long time. You had me at hello, or when you said dexilant and blockbuster....and then i realized, you dont know what the word "generic" means, and I fell into a deep slumber. I woke up to take a piss, laughed again when I recalled how you said OIC indication is growing Amitiza like "crazy," and then realized you don't know OIC's from your ABC's, poor, poor, child.
 




I shake my head and laugh at the 15 year flop Takeda has become
Has to be the biggest faceplant in pharma ever
Especially diabetes what a bunch of jokers

Take a look at the most recent top 100 drugs ranking
All your competitors are on it
Takeda is nowhere to be found

I can still remember@ 2009 at a national meeting,the positive buzz about Takeda being ranked 20th!Look how far we have dropped and we have those nutbags at the top to thank.You know,the ones that have never spent a day in the field,who feel they can tell us how to sell.Bunch of morons!